Signalling by the βc family of cytokines

Cytokine and Growth Factor Reviews

Volumn 24, Issue 3, 2013, Pages 189-201

  Hercus, Timothy R ^a   Dhagat, Urmi ^b   Kan, Winnie L T ^a   Broughton, Sophie E ^b   Nero, Tracy L ^b   Perugini, Michelle ^a   Sandow, Jarrod J ^c,d   D'Andrea, Richard J ^a   Ekert, Paul G ^c,d   Hughes, Timothy ^a   Parker, Michael W ^b,e   Lopez, Angel F ^a  

^a CENTRE FOR CANCER BIOLOGY   (Australia)

^b ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Common receptor; Cytokines; Inflammation; Leukaemia; Signalling

Indexed keywords

BENRALIZUMAB; BETA COMMON CYTOKINE; CSL 362; CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 3; INTERLEUKIN 3 RECEPTOR; INTERLEUKIN 5; INTERLEUKIN 5 RECEPTOR; JANUS KINASE 2; KB 003; MAVRILIMUMAB; MEPOLIZUMAB; MONOCLONAL ANTIBODY; MOR 103; MT 203; RESLIZUMAB; STAT5 PROTEIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADAPTIVE IMMUNITY; ASTHMA; AUTOIMMUNITY; CELL SURVIVAL; CHRONIC INFLAMMATION; COMPLEX FORMATION; CRYSTAL STRUCTURE; CYTOKINE PRODUCTION; HEMATOPOIESIS; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

Β COMMON RECEPTOR; CYTOKINES; INFLAMMATION; LEUKAEMIA; SIGNALLING;

ANIMALS; AUTOIMMUNITY; CYTOKINES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INFLAMMATION; INTERLEUKIN-3; INTERLEUKIN-5; JANUS KINASES; NF-KAPPA B; RECEPTORS, CYTOKINE; SIGNAL TRANSDUCTION;

EID: 84881254509     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2013.03.002     Document Type: Review

References (189)

1. Metcalf D. Hematopoietic cytokines. Blood 2008, 111:485-491.
2. Hercus T.R., Broughton S.E., Ekert P.G., Ramshaw H.S., Perugini M., Grimbaldeston M., et al. The GM-CSF receptor family: mechanism of activation and implications for disease. Growth Factors 2012, 30:63-75.
3. Lopez A.F., Hercus T.R., Ekert P., Littler D.R., Guthridge M., Thomas D., et al. Molecular basis of cytokine receptor activation. IUBMB Life 2010, 62:509-518.
4. Bradley T.R., Metcalf D. The growth of mouse bone marrow cells in vitro. Australian Journal of Experimental Biological Medicine Science 1966, 44:287-299.
5. Sheridan J.W., Metcalf D. A low molecular weight factor in lung-conditioned medium stimulating granulocyte and monocyte colony formation in vitro. Journal of Cellular Physiology 1973, 81:11-23.
6. Burgess A.W., Camakaris J., Metcalf D. Purification and properties of colony-stimulating factor from mouse lung-conditioned medium. The Journal of Biological Chemistry 1977, 252:1998-2003.
7. Gough N.M., Gough J., Metcalf D., Kelso A., Grail D., Nicola N.A., et al. Molecular cloning of cDNA encoding a murine haematopoietic growth regulator, granulocyte-macrophage colony stimulating factor. Nature 1984, 309:763-767.
8. Handman E., Burgess A.W. Stimulation by granulocyte-macrophage colony-stimulating factor of Leishmania tropica killing by macrophages. Journal of Immunology (Baltimore, Md.: 1950) 1979, 122:1134-1137.
9. Hamilton J.A., Stanley E.R., Burgess A.W., Shadduck R.K. Stimulation of macrophage plasminogen activator activity by colony-stimulating factors. Journal of Cellular Physiology 1980, 103:435-445.
10. Vadas M.A., Nicola N.A., Metcalf D. Activation of antibody-dependent cell-mediated cytotoxicity of human neutrophils and eosinophils by separate colony-stimulating factors. Journal of Immunology (Baltimore, Md.: 1950) 1983, 130:795-799.
11. Lopez A.F., Nicola N.A., Burgess A.W., Metcalf D., Battye F.L., Sewell W.A., et al. Activation of granulocyte cytotoxic function by purified mouse colony-stimulating factors. Journal of Immunology (Baltimore, Md.: 1950) 1983, 131:2983-2988.
12. Lopez A.F., Williamson D.J., Gamble J.R., Begley C.G., Harlan J.M., Klebanoff S.J., et al. Recombinant human GM-CSF stimulates in vitro mature human neutrophil and eosinophil function, surface receptor expression, and survival. The Journal of Clinical Investigation 1986, 78:1220-1228.
13. Metcalf D., Begley C.G., Johnson G.R., Nicola N.A., Vadas M.A., Lopez A.F., et al. Biologic properties in vitro of a recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1986, 67:37-45.
14. Cutler R.L., Metcalf D., Nicola N.A., Johnson G.R. Purification of a multipotential colony-stimulating factor from pokeweed mitogen-stimulated mouse spleen cell conditioned medium. The Journal of Biological Chemistry 1985, 260:6579-6587.
15. Clark-Lewis I., Schrader J.W. P cell-stimulating factor: biochemical characterization of a new T cell-derived factor. Journal of Immunology (Baltimore, Md.: 1950) 1981, 127:1941-1947.
16. Campbell H.D., Ymer S., Fung M.C., Young I.G. Cloning and nucleotide sequence of the murine interleukin-3 gene. European Journal of Biochemistry 1985, 150:297-304.
17. Lopez A.F., To L.B., Yang Y.C., Gamble J.R., Shannon M.F., Burns G.F., et al. Stimulation of proliferation, differentiation, and function of human cells by primate IL-3. Proceedings of the National Academy of Sciences of the United States of America 1987, 84:2761-2765.
18. Metcalf D., Begley C.G., Johnson N.A., Nicola N., Lopez A., Williamson D.J. Effects of purified bacterially synthesized murine multi-CSF (IL-3) on hemopoiesis in normal adult mice. Blood 1986, 68:46-57.
19. Sanderson C.J., Warren D.J., Strath M. Identification of a lymphokine that stimulates eosinophil differentiation in vitro. Its relationship to interleukin 3, and functional properties of eosinophils produced in cultures. The Journal of Experimental Medicine 1985, 162:60-74.
20. Campbell H.D., Tucker W.Q., Hort Y., Martinson M.E., Mayo G., Clutterbuck E.J., et al. Molecular cloning, nucleotide sequence, and expression of the gene encoding human eosinophil differentiation factor (interleukin 5). Proceedings of the National Academy of Sciences of the United States of America 1987, 84:6629-6633.
21. Lopez A.F., Sanderson C.J., Gamble J.R., Campbell H.D., Young I.G., Vadas M.A. Recombinant human interleukin 5 is a selective activator of human eosinophil function. The Journal of Experimental Medicine 1988, 167:219-224.
22. Sanderson C.J., O'Garra A., Warren D.J., Klaus G.G. Eosinophil differentiation factor also has B-cell growth factor activity: proposed name interleukin 4. Proceedings of the National Academy of Sciences of the United States of America 1986, 83:437-440.
23. Lopez A.F., Begley C.G., Williamson D.J., Warren D.J., Vadas M.A., Sanderson C.J. Murine eosinophil differentiation factor. An eosinophil-specific colony-stimulating factor with activity for human cells. The Journal of Experimental Medicine 1986, 163:1085-1099.
24. Walker F., Nicola N.A., Metcalf D., Burgess A.W. Hierarchial down-modulation of hemopoietic growth factor receptors. Cell 1985, 43:269-276.
25. Elliott M.J., Vadas M.A., Eglinton J.M., Park L.S., To L.B., Cleland L.G., et al. Recombinant human interleukin-3 and granulocyte-macrophage colony-stimulating factor show common biological effects and binding characteristics on human monocytes. Blood 1989, 74:2349-2359.
26. Lopez A.F., Eglinton J.M., Gillis D., Park L.S., Vadas M.A. Reciprocal inhibition of binding between interleukin 3 and granulocyte-macrophage colony-stimulating factor to human eosinophils. Proceedings of the National Academy of Sciences of the United States of America 1989, 86:7022-7026.
27. Lopez A.F., Eglington J.M., Lyons A.B., Tapley P.M., To L.B., Park L.S., et al. Human interleukin-3 inhibits the binding of granulocyte-macrophage colony-stimluating factor and interleukin-5 to basophils and strongly enhances their functional activity. Journal of Cellular Physiology 1990, 145:69-77.
28. Lopez A.F., Vadas M.A., Woodcock J.M., Milton S.E., Lewis A., Elliott M.J., et al. Interleukin-5, interleukin-3, and granulocyte-macrophage colony-stimulating factor cross-compete for binding to cell surface receptors on human eosinophils. The Journal of Biological Chemistry 1991, 266:24741-24747.
29. Lopez A.F., Elliott M.J., Woodcock J., Vadas M.A. GM-CSF, IL-3 and IL-5: cross-competition on human haemopoietic cells. Immunology Today 1992, 13:495-500.
30. Gearing D.P., King J.A., Gough N.M., Nicola N.A. Expression cloning of a receptor for human granulocyte-macrophage colony-stimulating factor. The EMBO Journal 1989, 8:3667-3676.
31. Kitamura T., Sato N., Arai K., Miyajima A. Expression cloning of the human IL-3 receptor cDNA reveals a shared β subunit for the human IL-3 and GM-CSF receptors. Cell 1991, 66:1165-1174.
32. Tavernier J., Devos R., Cornelis S., Tuypens T., Van der Heyden J., Fiers W., et al. A human high affinity interleukin-5 receptor (IL5R) is composed of an IL5-specific α chain and a β chain shared with the receptor for GM-CSF. Cell 1991, 66:1175-1184.
33. Wang X., Lupardus P., LaPorte S.L., Garcia K.C. Structural biology of shared cytokine receptors. Annual Review of Immunology 2009, 27:29-60.
34. Hercus T.R., Thomas D., Guthridge M.A., Ekert P.G., King-Scott J., Parker M.W., et al. The granulocyte-macrophage colony-stimulating factor receptor: linking its structure to cell signaling and its role in disease. Blood 2009, 114:1289-1298.
35. Vadas M.A., Nicola N., Lopez A.F., Metcalf D., Johnson G., Pereira A. Mononuclear cell-mediated enhancement of granulocyte function in man. Journal of Immunology (Baltimore, Md.: 1950) 1984, 133:202-207.
36. Codarri L., Gyulveszi G., Tosevski V., Hesske L., Fontana A., Magnenat L., et al. RORgammat drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nature Immunology 2011, 12:560-567.
37. El-Behi M., Ciric B., Dai H., Yan Y., Cullimore M., Safavi F., et al. The encephalitogenicity of T(H)17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF. Nature Immunology 2011, 12:568-575.
38. Mellman I., Steinman R.M. Dendritic cells: specialized and regulated antigen processing machines. Cell 2001, 106:255-258.
39. Lacey D.C., Achuthan A., Fleetwood A.J., Dinh H., Roiniotis J., Scholz G.M., et al. Defining GM-CSF- and macrophage-CSF-dependent macrophage responses by in vitro models. Journal of Immunology (Baltimore, Md.: 1950) 2012, 188:5752-5765.
40. Shibasaki T., Katayama N., Ohishi K., Fujieda A., Monma F., Nishi K., et al. IL-3 can not replace GM-CSF in inducing human monocytes to differentiate into Langerhans cells. International Journal of Oncology 2007, 30:549-555.
41. Fleetwood A.J., Cook A.D., Hamilton J.A. Functions of granulocyte-macrophage colony-stimulating factor. Critical Reviews in Immunology 2005, 25:405-428.
42. Metcalf D. The colony-stimulating factors and cancer. Nature Reviews. Cancer 2010, 10:425-434.
43. Mach N., Lantz C.S., Galli S.J., Reznikoff G., Mihm M., Small C., et al. Involvement of interleukin-3 in delayed-type hypersensitivity. Blood 1998, 91:778-783.
44. Rothenberg M.E., Owen W.F., Siberstein D.S., Woods J., Soberman R.J., Austen K.F., et al. Human eosinophils have prolonged survival, enhances functional properties, and become hypodense when exposed to human interleukin 3. The Journal of Clinical Investigation 1988, 81:1986-1992.
45. Ihle J.N. Interleukin-3 and hematopoiesis. Chemical Immunology 1992, 51:65-106.
46. Dahl C., Hoffmann H.J., Saito H., Schiotz P.O. Human mast cells express receptors for IL-3, IL-5 and GM-CSF; a partial map of receptors on human mast cells cultured in vitro. Allergy 2004, 59:1087-1096.
47. Lantz C.S., Boesiger J., Song C.H., Mach N., Kobayashi T., Mulligan R.C., et al. Role for interleukin-3 in mast-cell and basophil development and in immunity to parasites. Nature 1998, 392:90-93.
48. Kim S., Prout M., Ramshaw H., Lopez A.F., LeGros G., Min B. Cutting edge: basophils are transiently recruited into the draining lymph nodes during helminth infection via IL-3, but infection-induced Th2 immunity can develop without basophil lymph node recruitment or IL-3. Journal of Immunology (Baltimore, Md.: 1950) 2010, 184:1143-1147.
49. Sanderson C.J. Interleukin-5, eosinophils, and disease. Blood 1992, 79:3101-3109.
50. Denburg J.A., Silver J.E., Abrams J.S. Interleukin-5 is a human basophilopoietin: induction of histamine content and basophilic differentiation of HL-60 cells and of peripheral blood basophil-eosinophil progenitors. Blood 1991, 77:1462-1468.
51. Broide D.H., Paine M.M., Firestein G.S. Eosinophils express interleukin 5 and granulocyte macrophage-colony-stimulating factor mRNA at sites of allergic inflammation in asthmatics. The Journal of Clinical Investigation 1992, 90:1414-1424.
52. Ying S., Humbert M., Barkans J., Corrigan C.J., Pfister R., Menz G., et al. Expression of IL-4 and IL-5 mRNA and protein product by CD4+ and CD8+ T cells, eosinophils, and mast cells in bronchial biopsies obtained from atopic and nonatopic (intrinsic) asthmatics. Journal of Immunology (Baltimore, Md.: 1950) 1997, 158:3539-3544.
53. Nishinakamura R., Miyajima A., Mee P.J., Tybulewicz V.L.J., Murray R. Hematopoiesis in mice lacking the entire granulocyte-macrophage colony-stimulating factor/interleukin-3/interleukin-5 functions. Blood 1996, 88:2458-2464.
54. Suzuki T., Sakagami T., Rubin B.K., Nogee L.M., Wood R.E., Zimmerman S.L., et al. Familial pulmonary alveolar proteinosis caused by mutations in CSF2RA. The Journal of Experimental Medicine 2008, 205:2703-2710.
55. Suzuki T., Sakagami T., Young L.R., Carey B.C., Wood R.E., Luisetti M., et al. Hereditary pulmonary alveolar proteinosis: pathogenesis, presentation, diagnosis, and therapy. American Journal of Respiratory and Critical Care Medicine 2010, 182:1292-1304.
56. Griese M., Ripper J., Sibbersen A., Lohse P., Lohse P., Brasch F., et al. Long-term follow-up and treatment of congenital alveolar proteinosis. BMC Pediatrics 2011, 11:72.
57. Tanaka T., Motoi N., Tsuchihashi Y., Tazawa R., Kaneko C., Nei T., et al. Adult-onset hereditary pulmonary alveolar proteinosis caused by a single-base deletion in CSF2RB. Journal of Medical Genetics 2011, 48:205-209.
58. Inoue Y., Trapnell B.C., Tazawa R., Arai T., Takada T., Hizawa N., et al. Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan. American Journal of Respiratory and Critical Care Medicine 2008, 177:752-762.
59. Hamilton J.A. Colony-stimulating factors in inflammation and autoimmunity. Nature Reviews. Immunology 2008, 8:533-544.
60. Sokol C.L., Chu N.Q., Yu S., Nish S.A., Laufer T.M., Medzhitov R. Basophils function as antigen-presenting cells for an allergen-induced T helper type 2 response. Nature Immunology 2009, 10:713-720.
61. Perrigoue J.G., Saenz S.A., Siracusa M.C., Allenspach E.J., Taylor B.C., Giacomin P.R., et al. MHC class II-dependent basophil-CD4+ T cell interactions promote T(H)2 cytokine-dependent immunity. Nature Immunology 2009, 10:697-705.
62. Galli S.J., Kalesnikoff J., Grimbaldeston M.A., Piliponsky A.M., Williams C.M., Tsai M. Mast cells as "tunable" effector and immunoregulatory cells: recent advances. Annual Review of Immunology 2005, 23:749-786.
63. Hida S., Yamasaki S., Sakamoto Y., Takamoto M., Obata K., Takai T., et al. Fc receptor gamma-chain, a constitutive component of the IL-3 receptor, is required for IL-3-induced IL-4 production in basophils. Nature Immunology 2009, 10:214-222.
64. Kazazi F., Mathijs J.M., Chang J., Malafiej P., Lopez A., Dowton D., et al. Recombinant interleukin 4 stimulates human immunodeficiency virus production by infected monocytes and macrophages 2. The Journal of General Virology 1992, 73(Pt 4):941-949.
65. Begley C.G., Lopez A.F., Nicola N.A., Warren D.J., Vadas M.A., Sanderson C.J., et al. Purified colony-stimulating factors enhance the survival of human neutrophils and eosinophils in vitro: a rapid and sensitive microassay for colony-stimulating factors. Blood 1986, 68:162-166.
66. Guthridge M.A., Stomski F.C., Barry E.F., Winnall W., Woodcock J.M., McClure B.J., et al. Site-specific serine phosphorylation of the IL-3 receptor is required for hemopoietic cell survival. Molecular Cell 2000, 6:99-108.
67. Guthridge M.A., Barry E.F., Felquer F.A., McClure B.J., Stomski F.C., Ramshaw H., et al. The phosphoserine-585-dependent pathway of the GM-CSF/IL-3/IL-5 receptors mediates hematopoietic cell survival through activation of NF-kappaB and induction of bcl-2. Blood 2004, 103:820-827.
68. Olayioye M.A., Guthridge M.A., Stomski F.C., Lopez A.F., Visvader J.E., Lindeman G.J. Threonine 391 phosphorylation of the human prolactin receptor mediates a novel interaction with 14-3-3 proteins. The Journal of Biological Chemistry 2003, 278:32929-32935.
69. Mu F.T., Andrews R.K., Arthur J.F., Munday A.D., Cranmer S.L., Jackson S.P., et al. A functional 14-3-3zeta-independent association of PI3-kinase with glycoprotein Ib alpha, the major ligand-binding subunit of the platelet glycoprotein Ib-IX-V complex. Blood 2008, 111:4580-4587.
70. Hanazono Y., Sasaki K., Nitta H., Yazaki Y., Hirai H. Erythropoietin induces tyrosine phosphorylation of the beta chain of the GM-CSF receptor. Biochemical and Biophysical Research Communications 1995, 208:1060-1066.
71. Jubinsky P.T., Krijanovski O.I., Nathan D.G., Tavernier J., Sieff C.A. The beta chain of the interleukin-3 receptor functionally associates with the erythropoietin receptor. Blood 1997, 90:1867-1873.
72. Brines M., Grasso G., Fiordaliso F., Sfacteria A., Ghezzi P., Fratelli M., et al. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:14907-14912.
73. Brines M., Cerami A. The receptor that tames the innate immune response. Molecular Medicine 2012, 18:486-496.
74. Brines M., Patel N.S., Villa P., Brines C., Mennini T., De P.M., et al. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:10925-10930.
75. Bader A., Ebert S., Giri S., Kremer M., Liu S., Nerlich A., et al. Skin regeneration with conical and hair follicle structure of deep second-degree scalding injuries via combined expression of the EPO receptor and beta common receptor by local subcutaneous injection of nanosized rhEPO. International Journal of Nanomedicine 2012, 7:1227-1237.
76. Patel N.S., Kerr-Peterson H.L., Brines M., Collino M., Rogazzo M., Fantozzi R., et al. Delayed administration of pyroglutamate helix B surface peptide (pHBSP), a novel nonerythropoietic analog of erythropoietin, attenuates acute kidney injury. Molecular Medicine 2012, 18:719-727.
77. Emery P., Lopez A.F., Burns G.F., Vadas M.A. Synovial fluid neutrophils of patients with rheumatoid arthritis have membrane antigen changes that reflect activation. Annals of the Rheumatic Diseases 1988, 47:34-39.
78. Campbell I.K., Rich M.J., Bischof R.J., Dunn A.R., Grail D., Hamilton J.A. Protection from collagen-induced arthritis in granulocyte-macrophage colony-stimulating factor-deficient mice. Journal of Immunology (Baltimore, Md.: 1950) 1998, 161:3639-3644.
79. Hazenberg B.P., Van Leeuwen M.A., Van Rijswijk M.H., Stern A.C., Vellenga E. Correction of granulocytopenia in Felty's syndrome by granulocyte-macrophage colony-stimulating factor, simultaneous induction of interleukin-6 release and flare-up of the arthritis. Blood 1989, 74:2769-2770.
80. de Vries E.G., Willemse P.H., Biesma B., Stern A.C., Limburg P.C., Vellenga E. Flare-up of rheumatoid arthritis during GM-CSF treatment after chemotherapy. Lancet 1991, 338:517-518.
81. Cook A.D., Braine E.L., Campbell I.K., Rich M.J., Hamilton J.A. Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): requirement for GM-CSF in the effector phase of disease. Arthritis Research 2001, 3:293-298.
82. Campbell I.K., van N.A., Segura E., O'Donnell K., Coghill E., Hommel M., et al. Differentiation of inflammatory dendritic cells is mediated by NF-kappaB1-dependent GM-CSF production in CD4 T cells. Journal of Immunology (Baltimore, Md.: 1950) 2011, 186:5468-5477.
83. Cornish A.L., Campbell I.K., McKenzie B.S., Chatfield S., Wicks I.P. G-CSF and GM-CSF as therapeutic targets in rheumatoid arthritis. Nature Reviews. Rheumatology 2009, 5:554-559.
84. Young D.C., Wagner K., Griffin J.D. Constitutive expression of the granulocyte-macrophage colony-stimulating factor gene in acute myeloblastic leukemia. The Journal of Clinical Investigation 1987, 79:100-106.
85. Lajmanovich A., Berthier R., Schweitzer A., Leger J., Hollard D. Constitutive expression of GM-CSF mRNA by CML blast cells is correlated with endogenous megakaryocytic colony formation. Leukemia 1993, 7:1211-1218.
86. Riccioni R., Diverio D., Riti V., Buffolino S., Mariani G., Boe A., et al. Interleukin (IL)-3/granulocyte macrophage-colony stimulating factor/IL-5 receptor alpha and beta chains are preferentially expressed in acute myeloid leukaemias with mutated FMS-related tyrosine kinase 3 receptor. British Journal of Haematology 2009, 144:376-387.
87. Powell J.A., Thomas D., Barry E.F., Kok C.H., McClure B.J., Tsykin A., et al. Expression profiling of a hemopoietic cell survival transcriptome implicates osteopontin as a functional prognostic factor in AML. Blood 2009, 114:4859-4870.
88. Guthridge M.A., Powell J.A., Barry E.F., Stomski F.C., McClure B.J., Ramshaw H., et al. Growth factor pleiotropy is controlled by a receptor Tyr/Ser motif that acts as a binary switch. The EMBO Journal 2006, 25:479-489.
89. Hiwase D.K., White D.L., Powell J.A., Saunders V.A., Zrim S.A., Frede A.K., et al. Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors. Leukemia 2010, 24:771-778.
90. Lopez A.F., Lyons A.B., Eglinton J.M., Park L.S., To L.B., Clark S.C., et al. Specific binding of human interleukin-3 and granulocyte-macrophage colony-stimulating factor to human basophils. The Journal of Allergy and Clinical Immunology 1990, 85:99-102.
91. Lourenco F.D., Azor M.H., Santos J.C., Prearo E., Maruta C.W., Rivitti E.A., et al. Activated status of basophils in chronic urticaria leads to interleukin-3 hyper-responsiveness and enhancement of histamine release induced by anti-IgE stimulus. The British Journal of Dermatology 2008, 158:979-986.
92. Schroeder J.T., Chichester K.L., Bieneman A.P. Human basophils secrete IL-3: evidence of autocrine priming for phenotypic and functional responses in allergic disease. Journal of Immunology (Baltimore, Md.: 1950) 2009, 182:2432-2438.
93. Lampinen M., Carlson M., Hakansson L.D., Venge P. Cytokine-regulated accumulation of eosinophils in inflammatory disease. Allergy 2004, 59:793-805.
94. Jiang X., Lopez A., Holyoake T., Eaves A., Eaves C. Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America 1999, 96:12804-12809.
95. Delwel R., Dorssers L., Touw I., Wagemaker G., Lowenberg B. Human recombinant multilineage colony stimulating factor (interleukin-3): stimulator of acute myelocytic leukemia progenitor cells in vitro. Blood 1987, 70:333-336.
96. Jordan C.T., Upchurch D., Szilvassy S.J., Guzman M.L., Howard D.S., Pettigrew A.L., et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 2000, 14:1777-1784.
97. Testa U., Riccioni R., Militi S., Coccia E., Stellacci E., Samoggia P., et al. Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis. Blood 2002, 100:2980-2988.
98. Vergez F., Green A.S., Tamburini J., Sarry J.E., Gaillard B., Cornillet-Lefebvre P., et al. High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study. Haematologica 2011, 96:1792-1798.
99. Jin L., Lee E.M., Ramshaw H.S., Busfield S.J., Peoppl A.G., Wilkinson L., et al. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell 2009, 5:31-42.
100. Sun Q., Woodcock J.M., Rapoport A., Stomski F.C., Korpelainen E.I., Bagley C.J., et al. Monoclonal antibody 7G3 recognizes the N-terminal domain of the human interleukin-3 (IL-3) receptor α-chain and functions as a specific IL-3 receptor antagonist. Blood 1996, 87:83-92.
101. Korpelainen E.I., Gamble J.R., Smith W.B., Goodall G.J., Qiyu S., Woodcock J.M., et al. The receptor for interleukin 3 is selectively induced in human endothelial cells by tumor necrosis factor alpha and potentiates interleukin 8 secretion and neutrophil transmigration. Proceedings of the National Academy of Sciences of the United States of America 1993, 90:11137-11141.
102. Dentelli P., Del S.L., Rosso A., Molinar A., Garbarino G., Camussi G., et al. Human IL-3 stimulates endothelial cell motility and promotes in vivo new vessel formation. Journal of Immunology (Baltimore, Md.: 1950) 1999, 163:2151-2159.
103. Uberti B., Dentelli P., Rosso A., Defilippi P., Brizzi M.F. Inhibition of beta1 integrin and IL-3Rbeta common subunit interaction hinders tumour angiogenesis. Oncogene 2010, 29:6581-6590.
104. Lopez A.F., Williamson D.J., Gamble J.R., Begley C.G., Harlan J.M., Klebanoff S.J., et al. Recombinant human granulocyte-macrophage colony-stimulating factor stimulates in vitro mature human neutrophil and eosinophil function, surface receptor expression, and survival. The Journal of Clinical Investigation 1986, 78:1220-1228.
105. Humbert M., Corrigan C.J., Kimmitt P., Till S.J., Kay A.B., Durham S.R. Relationship between IL-4 and IL-5 mRNA expression and disease severity in atopic asthma. American Journal of Respiratory and Critical Care Medicine 1997, 156:704-708.
106. Lampinen M., Rak S., Venge P. The role of interleukin-5, interleukin-8 and RANTES in the chemotactic attraction of eosinophils to the allergic lung. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 1999, 29:314-322.
107. Garrett J.K., Jameson S.C., Thomson B., Collins M.H., Wagoner L.E., Freese D.K., et al. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. The Journal of Allergy and Clinical Immunology 2004, 113:115-119.
108. Rothenberg M.E., Klion A.D., Roufosse F.E., Kahn J.E., Weller P.F., Simon H.U., et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. The New England Journal of Medicine 2008, 358:1215-1228.
109. Pelaia G., Vatrella A., Maselli R. The potential of biologics for the treatment of asthma. Nature Reviews. Drug Discovery 2012, 11:958-972.
110. Kim H.Y., Dekruyff R.H., Umetsu D.T. The many paths to asthma: phenotype shaped by innate and adaptive immunity. Nature Immunology 2010, 11:577-584.
111. Asquith K.L., Ramshaw H.S., Hansbro P.M., Beagley K.W., Lopez A.F., Foster P.S. The IL-3/IL-5/GM-CSF common receptor plays a pivotal role in the regulation of Th2 immunity and allergic airway inflammation. Journal of Immunology (Baltimore, Md.: 1950) 2008, 180:1199-1206.
112. Burmester G.R., Feist E., Sleeman M.A., Wang B., White B., Magrini F. Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-alpha, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study. Annals of the Rheumatic Diseases 2011, 70:1542-1549.
113. Nair J.R., Edwards S.W., Moots R.J. Mavrilimumab, a human monoclonal GM-CSF receptor-alpha antibody for the management of rheumatoid arthritis: a novel approach to therapy. Expert Opinion on Biological Therapy 2012, 12:1661-1668.
114. Molfino N.A., Gossage D., Kolbeck R., Parker J.M., Geba G.P. Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 2012, 42:712-737.
115. Leckie M.J., ten B.A., Khan J., Diamant Z., O'Connor B.J., Walls C.M., et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000, 356:2144-2148.
116. Flood-Page P., Swenson C., Faiferman I., Matthews J., Williams M., Brannick L., et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. American Journal of Respiratory and Critical Care Medicine 2007, 176:1062-1071.
117. Nair P., Pizzichini M.M., Kjarsgaard M., Inman M.D., Efthimiadis A., Pizzichini E., et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. The New England Journal of Medicine 2009, 360:985-993.
118. Haldar P., Brightling C.E., Hargadon B., Gupta S., Monteiro W., Sousa A., et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. The New England Journal of Medicine 2009, 360:973-984.
119. Pavord I.D., Korn S., Howarth P., Bleecker E.R., Buhl R., Keene O.N., et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012, 380:651-659.
120. Sun Q., Jones K., McClure B., Cambareri B., Zacharakis B., Iversen P.O., et al. Simultaneous antagonism of interleukin-5, granulocyte-macrophage colony-stimulating factor, and interleukin-3 stimulation of human eosinophils by targetting the common cytokine binding site of their receptors. Blood 1999, 94:1943-1951.
121. 21 of GM-CSF. The EMBO Journal 1994, 13:5176-5185.
122. Woodcock J.M., Bagley C.J., Zacharakis B., Lopez A.F. A single tyrosine residue in the membrane-proximal domain of the GM-CSF, IL-3 and IL-5 receptor common β chain is necessary and sufficient for high affinity binding and signalling by all three ligands. The Journal of Biological Chemistry 1996, 271:25999-26006.
123. Barry S.C., Korpelainen E., Sun Q., Stomski F.C., Moretti P.A., Wakao H., et al. Roles of the N and C terminal domains of the interleukin-3 receptor alpha chain in receptor function. Blood 1997, 89:842-852.
124. Mulhern T.D., Lopez A.F., D'Andrea R.J., Gaunt C., Vandeleur L., Vadas M.A., et al. The solution structure of the cytokine-binding domain of the common β-chain of the receptors for granulocyte-macrophage colony-stimulating factor. Interleukin-3 and Interleukin-5. Journal of Molecular Biology 2000, 297:989-1001.
125. Murphy J.M., Ford S.C., Olsen J.E., Gustin S.E., Jeffrey P.D., Ollis D.L., et al. Interleukin-3 binding to the murine betaIL-3 and human betac receptors involves functional epitopes formed by domains 1 and 4 of different protein chains. The Journal of Biological Chemistry 2004, 279:26500-26508.
126. Murphy J.M., Young I.G. IL-3, IL-5, and GM-CSF signaling: crystal structure of the human beta-common receptor. Vitamins and Hormones 2006, 74:1-30.
127. Carr P.D., Gustin S.E., Church A.P., Murphy J.M., Ford S.C., Mann D.A., et al. Structure of the complete extracellular domain of the common beta subunit of the human GM-CSF, IL-3, and IL-5 receptors reveals a novel dimer configuration. Cell 2001, 104:291-300.
128. Hansen G., Hercus T.R., McClure B.J., Stomski F.C., Dottore M., Powell J., et al. The structure of the GM-CSF receptor complex reveals a distinct mode of cytokine receptor assembly. Cell 2008, 134:496-507.
129. Mirza S., Walker A., Chen J., Murphy J.M., Young I.G. The Ig-like domain of human GM-CSF receptor alpha plays a critical role in cytokine binding and receptor activation. The Biochemical Journal 2010, 426:307-317.
130. Yao S., Young I.G., Norton R.S., Murphy J.M. Murine interleukin-3: structure, dynamics, and conformational heterogeneity in solution. Biochemistry 2011, 50:2464-2477.
131. Broughton S.E., Dhagat U., Hercus T.R., Nero T.L., Grimbaldeston M.A., Bonder C.S., et al. The GM-CSF/IL-3/IL-5 cytokine receptor family: from ligand recognition to initiation of signaling. Immunological Reviews 2012, 250:277-302.
132. Diederichs K., Boone T., Karplus P.A. Novel fold and putative receptor binding site of granulocyte-macrophage colony-stimulating factor. Science 1991, 254:1779-1782.
133. Walter M.R., Cook W.J., Ealick S.E., Nagabhushan T.L., Trotta P.P., Bugg C.E. Three-dimensional structure of recombinant human granulocyte-macrophage colony-stimulating factor. Journal of Molecular Biology 1992, 224:1075-1085.
134. Feng Y., Klein B.K., McWherter C.A. Three-dimensional solution structure and backbone dynamics of a variant of human interleukin-3. Journal of Molecular Biology 1996, 259:524-541.
135. Milburn M.V., Hassel A.M., Lambert M.H., Jordan S.R., Proudfoot A.E.I., Graber P., et al. A novel dimer configuration revealed by the crystal structure at 2.4Å resolution of human interleukin-5. Nature 1993, 363:172-176.
136. Patino E., Kotzsch A., Saremba S., Nickel J., Schmitz W., Sebald W., et al. Structure analysis of the IL-5 ligand-receptor complex reveals a wrench-like architecture for IL-5Ralpha. Structure 2011, 19:1864-1875.
137. Kusano S., Kukimoto-Niino M., Hino N., Ohsawa N., Ikutani M., Takaki S., et al. Structural basis of interleukin-5 dimer recognition by its alpha receptor. Protein Science: A Publication of the Protein Society 2012, 21:850-864.
138. Dey R., Ji K., Liu Z., Chen L. A cytokine-cytokine interaction in the assembly of higher-order structure and activation of the interleukine-3: receptor complex. PLoS One 2009, 4:e5188.
139. De Vos A.M., Ultsch M., Kossiakoff A.A. Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science 1992, 255:306-312.
140. Broughton S.E., Hercus T.R., Lopez A.F., Parker M.W. Cytokine receptor activation at the cell surface. Current Opinion in Structural Biology 2012, 22:350-359.
141. Cornelis S., Plaetinck G., Devos R., Van der Heyden J., Tavernier J., Sanderson C.J., et al. Detailed analysis of the IL-5-IL-5R alpha interaction: characterization of crucial residues on the ligand and the receptor. The EMBO Journal 1995, 14:3395-3402.
142. Chen J., Olsen J., Ford S., Mirza S., Walker A., Murphy J.M., et al. A new isoform of interleukin-3 receptor {alpha} with novel differentiation activity and high affinity binding mode. The Journal of Biological Chemistry 2009, 284:5763-5773.
143. Hayashida K., Kitamura T., Gorman D.M., Arai K., Yokota T., Miyajima A. Molecular cloning of a second subunit of the receptor for human granulocyte-macrophage colony-stimulating factor (GM-CSF): reconstitution of a high-affinity GM-CSF receptor. Proceedings of the National Academy of Sciences of the United States of America 1990, 87:9655-9659.
144. Rossjohn J., McKinstry W.J., Woodcock J.M., McClure B.J., Hercus T.R., Parker M.W., et al. Structure of the activation domain of the GM-CSF/IL-3/IL-5 receptor common β chain bound to an antagonist. Blood 2000, 95:2491-2498.
145. Stomski F.C., Woodcock J.M., Zacharakis B., Bagley C.J., Sun Q., Lopez A.F. Identification of a Cys motif in the common β chain of the IL-3, GM-CSF and IL-5 receptors essential for disulfide-linked receptor heterodimerization and activation of all three receptors. The Journal of Biological Chemistry 1998, 273:1192-1199.
146. Carr P.D., Conlan F., Ford S., Ollis D.L., Young I.G. An improved resolution structure of the human beta common receptor involved in IL-3 IL-5 and GM-CSF signalling which gives better definition of the high-affinity binding epitope. Acta Crystallographica. Section F, Structural Biology and Crystallization Communications 2006, 62:509-513.
147. Murphy J.M., Ford S.C., Wiedemann U.M., Carr P.D., Ollis D.L., Young I.G. A novel functional epitope formed by domains 1 and 4 of the human common beta-subunit is involved in receptor activation by granulocyte macrophage colony-stimulating factor and interleukin 5. The Journal of Biological Chemistry 2003, 278:10572-10577.
148. Lopez A.F., Shannon M.F., Barry S., Phillips J.A., Cambareri B., Dottore M., et al. A human Interleukin-3 analog with increased biological and binding activities. Proceedings of the National Academy of Sciences of the United States of America 1992, 89:11842-11846.
149. Hercus T.R., Bagley C.J., Cambareri B., Dottore M., Woodcock J.M., Vadas M.A., et al. Specific human granulocyte-macrophage colony-stimulating factor antagonists. Proceedings of the National Academy of Sciences of the United States of America 1994, 91:5838-5842.
150. Lopez A.F., Shannon M.F., Hercus T., Nicola N.A., Cambareri B., Dottore M., et al. Residue 21 of human granulocyte-macrophage colony-stimulating factor is critical for biological activity and for high but not low affinity binding. The EMBO Journal 1992, 11:909-916.
151. 22, selectively interact with the α- and β-chains of its receptor and participate in function. The Journal of Biological Chemistry 1994, 269:8488-8492.
152. Bagley C.J., Woodcock J.M., Stomski F.C., Lopez A.F. The structural and functional basis of cytokine receptor activation: lessons from the common β subunit of the granulocyte-macrophage colony-stimulating factor, interleukin-3 (IL-3) and IL-5 receptors. Blood 1997, 89:1471-1482.
153. Tavernier J., Tuypens T., Verhee A., Plaetinck G., Devos R., Van der Heyden J., et al. Identification of receptor-binding domains on human interleukin 5 and design of an interleukin 5-derived receptor antagonist. Proceedings of the National Academy of Sciences of the United States of America 1995, 92:5194-5198.
154. Broxmeyer H.E., Hoggatt J., O'Leary H.A., Mantel C., Chitteti B.R., Cooper S., et al. Dipeptidylpeptidase 4 negatively regulates colony-stimulating factor activity and stress hematopoiesis. Nature Medicine 2012, 18:1786-1796.
155. Chen P.H., Chien F.C., Lee S.P., Chan W.E., Lin I.H., Liu C.S., et al. Identification of a novel function of the clathrin-coated structure at the plasma membrane in facilitating GM-CSF receptor-mediated activation of JAK2. Cell Cycle 2012, 11:3611-3626.
156. Ungureanu D., Saharinen P., Junttila I., Hilton D.J., Silvennoinen O. Regulation of Jak2 through the ubiquitin-proteasome pathway involves phosphorylation of Jak2 on Y1007 and interaction with SOCS-1. Molecular and Cellular Biology 2002, 22:3316-3326.
157. Kamizono S., Hanada T., Yasukawa H., Minoguchi S., Kato R., Minoguchi M., et al. The SOCS box of SOCS-1 accelerates ubiquitin-dependent proteolysis of TEL-JAK2. The Journal of Biological Chemistry 2001, 276:12530-12538.
158. Ungureanu D., Wu J., Pekkala T., Niranjan Y., Young C., Jensen O.N., et al. The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling. Nature Structural & Molecular Biology 2011, 18:971-976.
159. Lei J.T., Mazumdar T., Martinez-Moczygemba M. Three lysine residues in the common beta chain of the interleukin-5 receptor are required for Janus kinase (JAK)-dependent receptor ubiquitination, endocytosis, and signaling. The Journal of Biological Chemistry 2011, 286:40091-40103.
160. Chaturvedi P., Reddy M.V., Reddy E.P. Src kinases and not JAKs activate STATs during IL-3 induced myeloid cell proliferation. Oncogene 1998, 16:1749-1758.
161. Itoh T., Liu R., Yokota T., Arai K.-I., Watanabe S. Definition of the role of tyrosine residues of the common beta subunit regulating multiple signaling pathways of granulocyte-macrophage colony-stimulating factor receptor. Molecular & Cellular Biology 1998, 18:742-752.
162. Ramshaw H.S., Guthridge M.A., Stomski F.C., Barry E.F., Ooms L., Mitchell C.A., et al. The Shc binding site of the βc subunit of the GM-CSF/IL-3/IL-5 receptors is a negative regulator of hematopoiesis. Blood 2007, 110:3582-3590.
163. Okuda K., Smith L., Griffin J.D., Foster R. Signaling functions of the tyrosine residues in the betac chain of the granulocyte-macrophage colony-stimulating factor receptor. Blood 1997, 90:4759-4766.
164. Dijkers P.F., van Dijk T.B., De Groot R.P., Raaijmakers J.A., Lammers J.W., Koenderman L., et al. Regulation and function of protein kinase B and MAP kinase activation by the IL-5/GM-CSF/IL-3 receptor. Oncogene 1999, 18:3334-3342.
165. Polotskaya A., Zhao Y., Lilly M.L., Kraft A.S. A critical role for the cytoplasmic domain of the granulocyte- macrophage colony-stimulating factor alpha receptor in mediating cell growth. Cell Growth & Differentiation 1993, 4:523-531.
166. Weiss M., Yokoyama C., Shikama Y., Naugle C., Druker B., Sieff C.A. Human granulocyte-macrophage colony-stimulating factor receptor signal transduction requires the proximal cytoplasmic domains of the α and β subunits. Blood 1993, 82:3298-3306.
167. Dhar-Mascareno M., Chen J., Zhang R.H., Carcamo J.M., Golde D.W. Granulocyte-macrophage colony-stimulating factor signals for increased glucose transport via phosphatidylinositol 3-kinase- and hydrogen peroxide-dependent mechanisms. The Journal of Biological Chemistry 2003, 278:11107-11114.
168. Perugini M., Brown A.L., Salerno D.G., Booker G.W., Stojkoski C., Hercus T.R., et al. Alternative modes of GM-CSF receptor activation revealed using activated mutants of the common beta-subunit. Blood 2010, 115:3346-3353.
169. Ebner K., Bandion A., Binder B.R., de M.R., Schmid J.A. GMCSF activates NF-kappaB via direct interaction of the GMCSF receptor with IkappaB kinase beta. Blood 2003, 102:192-199.
170. D'Andrea R., Rayner J., Moretti P., Lopez A., Goodall G.J., Gonda T.J., et al. A mutation of the common receptor subunit for interleukin-3 (IL-3), granulocyte-macrophage colony-stimulating factor, and IL-5 that leads to ligand independence and tumorigenicity. Blood 1994, 83:2802-2808.
171. McCormack M.P., Gonda T.J. Expression of activated mutants of the human interleukin-3/interleukin- 5/granulocyte-macrophage colony-stimulating factor receptor common beta subunit in primary hematopoietic cells induces factor-independent proliferation and differentiation. Blood 1997, 90:1471-1481.
172. McCormack M.P., Gonda T.J. Novel murine myeloid cell lines that exhibit a differentiation switch in response to IL-3 or GM-CSF, or to different constitutively active mutants of the GM-CSF receptor beta subunit. Blood 2000, 95:120-127.
173. D'Andrea R.J., Gonda T.J. A model for assembly and activation of the GM-CSF, IL-3 and IL-5 receptors: insights from activated mutants of the common beta subunit. Experimental Hematology 2000, 28:231-243.
174. Courtois G., Gilmore T.D. Mutations in the NF-kappaB signaling pathway: implications for human disease. Oncogene 2006, 25:6831-6843.
175. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006, 441:431-436.
176. Hayden M.S., Ghosh S. Shared principles in NF-kappaB signaling. Cell 2008, 132:344-362.
177. Grumont R.J., Rourke I.J., Gerondakis S. Rel-dependent induction of A1 transcription is required to protect B cells from antigen receptor ligation-induced apoptosis. Genes & Development 1999, 13:400-411.
178. Grossmann M., O'Reilly L.A., Gugasyan R., Strasser A., Adams J.M., Gerondakis S. The anti-apoptotic activities of Rel and RelA required during B-cell maturation involve the regulation of Bcl-2 expression. The EMBO Journal 2000, 19:6351-6360.
179. Sandow J.J., Jabbour A.M., Condina M.R., Daunt C.P., Stomski F.C., Green B.D., et al. Cytokine receptor signaling activates an IKK-dependent phosphorylation of PUMA to prevent cell death. Cell Death and Differentiation 2012, 19:633-641.
180. Hacker H., Karin M. Regulation and function of IKK and IKK-related kinases. Science's STKE: Signal Transduction Knowledge Environment 2006, 2006:re13.
181. Rothwarf D.M., Zandi E., Natoli G., Karin M. IKK-gamma is an essential regulatory subunit of the IkappaB kinase complex. Nature 1998, 395:297-300.
182. DiDonato J.A., Hayakawa M., Rothwarf D.M., Zandi E., Karin M. A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB. Nature 1997, 388:548-554.
183. Yamaoka S., Courtois G., Bessia C., Whiteside S.T., Weil R., Agou F., et al. Complementation cloning of NEMO, a component of the IkappaB kinase complex essential for NF-kappaB activation. Cell 1998, 93:1231-1240.
184. Zandi E., Rothwarf D.M., Delhase M., Hayakawa M., Karin M. The IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, necessary for IkappaB phosphorylation and NF-kappaB activation. Cell 1997, 91:243-252.
185. Rahighi S., Ikeda F., Kawasaki M., Akutsu M., Suzuki N., Kato R., et al. Specific recognition of linear ubiquitin chains by NEMO is important for NF-kappaB activation. Cell 2009, 136:1098-1109.
186. Hadian K., Griesbach R.A., Dornauer S., Wanger T.M., Nagel D., Metlitzky M., et al. NF-kappaB essential modulator (NEMO) interaction with linear and lys-63 ubiquitin chains contributes to NF-kappaB activation. The Journal of Biological Chemistry 2011, 286:26107-26117.
187. Meads M.B., Li Z.W., Dalton W.S. A novel TNF receptor-associated factor 6 binding domain mediates NF-kappa B signaling by the common cytokine receptor beta subunit. Journal of Immunology (Baltimore, Md.: 1950) 2010, 185:1606-1615.
188. Besancon F., Atfi A., Gespach C., Cayre Y.E., Bourgeade M.F. Evidence for a role of NF-kappaB in the survival of hematopoietic cells mediated by interleukin 3 and the oncogenic TEL/platelet-derived growth factor receptor beta fusion protein. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:8081-8086.
189. Fricker M., O'Prey J., Tolkovsky A.M., Ryan K.M. Phosphorylation of Puma modulates its apoptotic function by regulating protein stability. Cell Death Disease 2010, 1:e59.